Search | IOVS | ARVO Journals

View

Showing 1 – 5 of 5

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract April 2014

Differential Expression of IRBP, Albumin, BIGH3 and PNA Binding in the Interphotoreceptor Matrix Versus Choroid in Diabetes, AMD and Glaucoma

Andrew T C Tsin; Tianle Zou; Richard LeBaron; Veronica Gonzalez-Fernandez; Pamela Hires; John Lonsdale; Federico Gonzalez-Fernandez

Invest. Ophthalmol. Vis. Sci.. 2014; 55(13):6013. doi:

ARVO Annual Meeting Abstract June 2013

Lifitegrast 5.0% Ophthalmic Solution Reduces Ocular Surface Staining and Improves Symptoms in Patients with Dry Eye Disease: Results of a Phase 3 Study (OPUS-1)

Charles Semba; Gail Torkildsen; Francis D'Ambrosio; John Lonsdale; Eugene McLaurin; Richard Eiferman; Kathryn Kennedy; John Sheppard; OPUS-1 Investigators

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):2669. doi:

ARVO Annual Meeting Abstract June 2013

Differential Expression of IRBP, Albumin, BIGH3 and PNA Binding in the Interphotoreceptor Matrix Versus Choroid in Diabetes, AMD and Glaucoma

Federico Gonzalez-Fernandez; Tianle Zou; Richard Lebaron; Andrew Tsin; John Lonsdale

Invest. Ophthalmol. Vis. Sci.. 2013; 54(15):732. doi:

ARVO Annual Meeting Abstract March 2012

Safety and Efficacy of Topical Ophthalmic MIM-D3, a Novel TrkA Receptor Agonist, in a Phase 2 Clinical Trial for the Treatment of Dry Eye

Karen Meerovitch; Gail Torkildsen; John Lonsdale; Heidi Goldfarb; Teresa Lama; Garth Cumberlidge; George W. Ousler, III

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):578. doi:

ARVO Annual Meeting Abstract April 2011

A Phase 2 Multicenter, Double-masked, Placebo-controlled Study Of A Novel Lymphocyte Function-associated Antigen-1 (LFA-1) Antagonist (SAR 1118) For Treatment Of Dry Eye

Charles P. Semba; Gail Torkildsen; John Lonsdale; Eugene McLaurin; Joel Geffin; Thomas Mundorf; Kathryn Kennedy; George Ousler

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):3823. doi:

Advertisement